FLT3 and acute myeloid leukemia: As illustrated in Figure 3D, mice engrafted with patient-derived FLT3-ITD+ AML cells were treated with vehicle, quizartinib, or everolimus alone, or these drugs in combination for 5 days to assess the short-term effects of these therapies on leukemic burden in the spleen and BM.